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The Lack of Environmental
Justice in Central and Eastern
Europe 
The conclusion of the recent EHP mono-
graph on environmental justice (Shepard et
al. 2002) is that environmental exposures
and environmental health issues impact dis-
proportionately on vulnerable populations.
In Central and Eastern Europe, we envi-
ously read about the studies (primarily
American) carried out in this field. As a con-
sequence of the lack of moral, political and
financial support, this type of research is
currently not possible in this area of Europe.
In fact, Central and Eastern Europe
would be an excellent model area for this
type of study. The total area of six to eight
countries in Central and Eastern Europe is
equivalent to that of one of the smaller states
in the United States. Because the countries
are small, environmental pollution easily
crosses the borders, which are most fre-
quently political and are rarely geographical
or hydrological (i.e., natural). The pollution
often affects the health of populations of
adjacent countries. Sometimes environmen-
tally irresponsible behavior is a consequence
of the past. Unfortunately, articles that focus
on the historical and political background of
current environmental situations in Central
and Eastern Europe are not frequently found
in the literature. [At this point the reader
may ask why we do not write one. We did
write an article about the Carpathian Basin
(Varga et al. Unpublished data), but EHP
would not publish it because of the political
nature of the manuscript.] However, an arti-
cle that does not investigate the true causes
of the problems is meaningless. In other
words, it is not the articles, but the problems
themselves, that are saturated with politics.
In order to solve the problems, it is necessary
to face them head on.
Faber and Krieg (2002) suggested that,
in Massachusetts, the “ecologically hazardous
sites and facilities are disproportionately
located and concentrated in communities of
color and working-class communities.” This
is also true for other locations in the United
States. There are many similar examples in
Central and Eastern Europe, such as a recent
scandal in Hungary: After the country’s
largest sports hall was destroyed by fire, the
debris containing crocidolite asbestos was
dumped illegally in an empty site close to a
working-class housing district in Budapest. 
In some countries in Central and Eastern
Europe, environmentally hazardous sites and
activities are also disproportionally located,
with high concentrations in the areas and
communities of ethnic or national minori-
ties. In the majority of countries in Central
and Eastern Europe, the classical term of eth-
nic minority predominantly means the
Romany (gypsy) population. For example, in
the case of a Hungarian Romany community
in Heves, where 1,500 persons were exposed
to high doses of lead as a consequence of the
illegal disassembly of car batteries collected
from nearby dumps and gas stations, one 15-
month-old girl died and 65 children and 14
adults were hospitalized (Varró et al. 2001).
National minorities are often subjects of
environmental injustice. These minorities
are primarily products of political and gov-
ernmental changes in the twentieth century,
when millions of people suddenly found
themselves living in a different country
while still in their own homes, depending
on the interests of great powers. That is,
because the region where they lived was
absorbed by another country, the residents
frequently became second class citizens of
their new state. This has been a common
occurrence (both as enclaves and as com-
pact zones along the borders) from the
Baltic Sea to the Balkans (Brown 1999,
Varga and Ember 2000). 
Manipulated industrialization was a char-
acteristic feature of the fallen national com-
munist regimes. These environmental “hot
spots” exist today, exposing residents of sev-
eral countries to long-term or permanent haz-
ards. Neighboring countries can be exposed
to potential environmental risks; for example,
there are international debates on nuclear
power plants (e.g., Czech Republic vs.
Austria, Slovakia vs. Austria and Hungary);
atmospheric pollution (e.g., Poland vs.
Germany), and river pollution (upstream vs.
downstream countries). Research in environ-
mental justice is urgently needed to aid in the
resolution of environmental issues.
Both scientifically and politically unique
issues have also arisen in Cental and Eastern
Europe. The recent environmental catastro-
phe in the Carpathian Basin was caused by
an Australian–Romanian joint venture in
Baia Mare/Nagybánya, Romania, inhabited
primarily by ethnic Hungarians. The com-
pany used (and currently uses) hazardous
technology for gold production, which is not
allowed in many other countries (e.g.,
Australia). In January 2000, the mine dis-
charged almost 100,000 m3 of concentrated
cyanide solution and polluted the Hungarian
section of the Tisza River through the
Szamos catchment area. The total quantity
of cyanide (in the pollution wave) was
approximately 105–110 tons; 70–100 tons
of copper was also detected. This pollution
almost completely killed the plankton in the
Tisza and Szamos Rivers. The most spectac-
ular consequence of this cyanide pollution,
however, was an enormous fish kill, esti-
mated at 1,241 tons. Fortunately, drinking-
water production for the involved cities was
stopped in time to prevent massive human
exposure (Standovár and Primack 2001). In
this case, Romanian producers with
Australian capital caused both ecologic and
economic damage as well as a health hazard
for the Hungarian population. [Indeed,
new mines with the same technology are
planned (e.g., Verespatak project with
Canadian capital). It is a new type of eco-
colonialism.] To date, both Hungary and
the company are still debating on which
country’s laws should be used in the com-
pensation trial. Meanwhile, the joint ven-
ture was cleared in a criminal suit in the
Romanian court, but the European Union
Inspection Committee declared that the
company is responsible for the ecologic cat-
astrophe (European Commission 2001).
Another example is the Danube Dam
Project. The goal of the Danube Dam
Project, began in the communist era, was to
effectively use the Danube River, which in
this area forms the border between Slovakia
and Hungary. Hungary withdrew from the
project following the change of the govern-
ment to a democracy. The Slovak Academy
of Sciences called attention to fact that the
project could cause contamination of drink-
ing water in Csallóköz (Slovakian territory
north of the Danube with a Hungarian pop-
ulation). The Danube was redirected into an
artificial canal in Slovakia to a new hydro-
electric power plant, bypassing the Old
Danube (the frontier river). This operation
caused an extraordinary decrease in surface
water, leading to a decrease in the water
table in the Hungarian Szigetköz and thus
causing branches, channels, and backwaters
of the river to dry up, threatening the
unique biotopes. Transportation on the
river was also redirected to Slovak territory,
leading to even more legal disputes.
Although the International Court (1997)
decided that water distribution should be
the subject of bilateral negotiations, to date,
the problems still have not been resolved. 
This situation with the Danube Dam
Project is also special in that ethnic
Hungarians live on both the Slovakian and
Hungarian sides of the river. This population
bears the environmental risks and disadvan-
tages, while others receive the benefits.
Severe ecologic issues have already arisen in
the Hungarian Szigetköz with drying up of
river tributaries, but most of the problems in
Hungarian communities in the Slovakian
territory (e.g., isolation by the artificial canal)
are sociologic in nature. Similar situations
may have also occurred in other countries.
Who benefits, and who bears the costs?
In Central and Eastern Europe, interna-
tional dimensions are especially complicated
by the political history of the region.
Scientific research is needed to address the
environmental injustice of international
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Proposed PBPK Model to
Predict Infant Exposure to
Toxic Chemicals in Breast Milk 
In the mini-monograph, “Pharmacokinetics
of Toxic Chemicals in Breast Milk: Use of
PBPK Models to Predict Infant Exposure,”
published in the June issue of Environmental
Health Perspectives, Clewell and Gearhart
(2002) described a model schematic devel-
oped in rats for the lactational transfer of per-
chlorate and iodide from the mother to the
neonate. They used this physiologically based
pharmacokinetic (PBPK) model to predict
the distribution of perchlorate and iodide in
lactating mothers and in infants in humans.
It is thought that because of its similarity
in ionic size to iodide, the perchlorate ion is a
competitive inhibitor of iodide at the sodium
iodide symporter (NIS), the plasma mem-
brane protein that catalyzes the accumulation
of iodide into thyroid cells (Wolff 1998).
The perchlorate ion blocks the binding of
iodide to the NIS and is not internalized by
the NIS into the thyroid cell (De La Vieja et
al. 2000). Perchlorate can accumulate in the
thyroid but does not seem to accumulate in
the thyrocytes (Eskandari et al. 1997).
Perchlorate is excreted intact in the urine and
has a half-life in humans of about 6–8 hr.
Approximately 95% is recovered in the urine
over 72 hr (Eichler 1929). Perchlorate is
excreted quickly and is not stored, but
enough iodine is stored in humans for about
6 weeks.
The PBPK model described by Clewell
and Gearhart (2002) is a “schematic of the
lactation model for the rat and human.”
The rat model was included in the March
2002 external review draft in preparation
for the U.S. Environmental Protection
Agency Toxicological Review and Draft
Risk Characterization meeting held 5–6
March 2002 in Sacramento, California. At
the meeting Nancy Carrasco, whose team
sequenced and cloned the NIS (Dai et al.
1996), repeatedly claimed that perchlorate
is not internalized by the thyroid cells.
Additionally, NIS sites have not been
found in human skin (Ajjan et al. 1998;
Vayre et al. 1999).
Perchlorate has been in medical use
since the 1950s, primarily for the treatment
of hyperthyroidism; it is still in clinical use
today mainly for diagnostic purposes. The
toxicity of perchlorate in humans is known,
as is its dose response in humans who have
been exposed therapeutically, occupation-
ally, in clinical studies, or environmentally
via drinking water (Soldin et al. 2001).
Iodide inhibition will not cause adverse
effects on humans if thyroid hormone levels
remain normal. Assuming a daily intake of
2L   water/day, the highest known level of
perchlorate in drinking water (24 µg/L)
would yield a daily exposure of less than 50
µg/day. This seems a large range of safety,
being 10-fold lower than the 500 µg/day
level that Greer et al. (2002) considered to
be the no-effect level in humans for the
inhibition by perchlorate of iodine uptake
by the thyroid, the mode-of-action held to
be the initial and essential pharmacologic
effect of perchlorate. It is also a thousand-
fold lower than the 50 mg/day level at
which an effect on thyroid hormone levels
in humans may be expected. The absence of
an observed effect on neonatal thyroid, thy-
roidal diseases, or thyroidal cancer in areas
with higher detected perchlorate levels is
epidemiologically consistent with the
human toxicologic and pharmacologic
observations. 
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Proposed PBPK Model to
Predict Infant Exposure:
Clewell and Gearhart’s
Response 
In her letter, Soldin makes a number of
points regarding the potential human toxic-
ity of perchlorate (ClO4
–), one of the chem-
icals mentioned in our paper (Clewell and
Gearhart 2002). The purpose of our article
(Clewell and Gearhart 2002) was to
describe the potential use of physiologically
based pharmacokinetic (PBPK) modeling
to address the challenges encountered in
calculating chemical transfer in breast milk.
We presented ClO4
– as one of several
examples of how PBPK modeling can be
used to predict neonatal dose where little or
no data are available in humans. The model
includes descriptions for ClO4
– and iodide
in the lactating rat and neonate and the
extrapolation of radioiodide to human lac-
tation. We suggested that the successful
extrapolation of the rat radioiodide model
to predict human milk increases confidence
in using a similar PBPK-based approach to
estimate infant ClO4
– dose (Clewell and
Gearhart 2002). 
With respect to the PBPK model for
ClO4
–, Soldin expresses concern regarding
the model structure, stating that ClO4
– is not
transported into the thyrocyte. This con-
tention is based solely on in vitro electro-
genicity studies in frog oocytes (Eskandari et
al. 1997) and Chinese hamster ovary cells
(Yoshida et al. 2002), the results of which are
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blocks I– transport but is not transferred into
the thyroid, and b) ClO4
– competes with I–
and is transported by sodium iodide sym-
porter (NIS) at a 1:1 ratio with Na+ (Dohan
et al. 2000; Nilsson 1999; Riedel et al.
2001a, 2001b). These three studies did not
measure thyroid ClO4
– levels, nor did they
offer concrete evidence disproving the
translocation of ClO4
– into the follicle. 
Perchlorate transfer into the thyrocyte is
evidenced by the effect of ClO4
– on inter-
nalized thyroid iodide (Hildebrandt and
Halmi 1981). In the presence of propylth-
iouracil (which blocks iodide organification)
and thyroid stimulating hormone (which
increases inorganic iodide uptake), ClO4
–
exposure caused a significant discharge of
the internal iodide. This suggests that ClO4
–
enters the thyroid cell and displaces iodide
from binding sites in the thyrocyte. 
The model description is also supported
by measured thyroid:serum ClO4
– ratios > 1
and up to 30 (Chow and Woodbury 1970;
Yu et al. 2002a). These high anion concen-
trations cannot be explained without active
sequestration, and the possibility of analyti-
cal interference by metabolites is ruled out
by a double-labeled 36Cl18O4
– study that
showed no appreciable metabolism in the
rat (Anbar et al. 1959). Furthermore, time-
course data show two distinct phases in
ClO4
– uptake in the thyroid (half-life = 2
and 33 min), which Chow and Woodbury
(1970) suggested represent the rapid trans-
port into the interstitial and cellular com-
partments and the slow equilibration in the
luminal fluid, respectively. This same behav-
ior was also observed in the clearance curve
from an intravenous dose (Yu et al. 2002a).
Thus, when taken together, the weight of
evidence suggests that ClO4
– is a truly com-
petitive inhibitor (Chow and Woodbury
1970; Hildebrandt and Halmi 1981; Wolff
1998; Yu et al. 2002a). Our mode of action
hypothesis, which served as the foundation
for the kinetic models, was based upon the
entire body of available information. 
A second concern mentioned by Soldin
was the inclusion of active uptake of ClO4
–
in the skin. In the model, the skin compart-
ment actively sequesters ClO4
– and iodide
from the blood but is not a route of entry.
This description of ion transport in the skin
is supported by the presence of NIS (Kotani
et al. 1998) and the accumulation of iodide
and ClO4
– in rat skin (Brown-Grant 1959;
Yu et al. 2002a), as well as ClO4
–-induced
inhibition of iodide uptake in the skin of
fetal and neonatal rats (Yu et al. 2002b;
Zeghal et al. 1995). Because the skin is not
the target tissue, it is not critical to prove
the mode of ion transport. However, it is
important to accurately describe skin con-
centrations, since blood levels and, there-
fore, milk transfer and thyroid kinetics,
could be affected by the transfer into such a
large organ. 
Finally, Soldin suggests that the
dose–response relationship for ClO4
– toxic-
ity is known from a variety of human expo-
sure scenarios. We contend, however, that
quantitative information on dose response
in humans is incomplete at best and essen-
tially nonexistent in the newborn. Although
thyroid hormones have been measured in
ClO4
–-exposed infants and children in epi-
demiologic studies (Crump et al. 2000;
Lamm and Doemland 1999; Li et al.
2000), neurologic end points have not been
correlated to a neonatal ClO4
– dose.
Because ClO4
– inhibits iodide uptake in the
thyroid and in milk (Brown-Grant 1957;
Potter et al. 1959; Howard et al. 1996) and
is present in the milk of lactating rats
(Clewell and Gearhart 2002), it would seem
prudent to quantitatively determine the
extent of neonatal exposure to ClO4
– and
the resulting inhibition of neonatal thyroid
iodide. The PBPK models presented in our
paper (Clewell and Gearhart 2002) enable
us to develop a reasonable estimate of dose
in the population of interest, the human
neonate, thereby providing a vital piece of
information needed for a more informed
human health risk assessment. 
Rebecca A. Clewell
Geo-Centers, Inc. 
Wright-Patterson AFB, Ohio
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Dayton, Ohio
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Personal and Political Aspects
of MCS
Thank you for the August 2002
Environmental Health Perspectives
Supplement on “Air Toxics and Asthma”
and “Environmental Factors in Medically
Unexplained Diseases” [Environ Health
Perspect 110(suppl 4)]. I am pleased to see
the recommendations for research on ill-
nesses such as chronic fatigue syndrome,
fibromyalgia, sick-building syndrome, and
multiple chemical sensitivities (MCS). 
For several years I have had reactions to
many scented products, auto exhaust, some
plastics and inks, and numerous household
chemicals. I have had allergies most of my
life, which are well managed by medication.
Chemical sensitivities have been more of a
hardship than allergies and, to my knowl-
edge, avoidance is the only effective therapy.
Years ago, I had a short-term illness after
using furniture stripper, and years later, I had
a long-term illness following repeated use of
a 12.8% lindane solution. As my sensitivities
increased, repeated chemical exposures in
daily life brought me chronic and debilitat-
ing fatigue, intermittent severe stabbing pain,
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loss of bladder control, loss of coordination,
nose bleeds, respiratory problems, disorienta-
tion, and vasculitis in my hands and feet. 
Since then, I have removed many house-
hold cleaning products and personal care
products from my home. It is almost impos-
sible to keep heavily scented products from
entering the home on packaging, plastics,
store items, and clothes worn by visitors.
Avoiding chemicals that commonly cause
symptoms of illness in sensitive persons is
difficult and violates social norms. Avoidance
of irritants has significantly improved my
general health and energy level, and accom-
modation at work has allowed me to avoid
newly remodeled areas and scented personal
care products of co-workers. 
Chemical and pharmaceutical compa-
nies have an enormous stake in the medical
coding of MCS as a psychologic rather
than a physiologic illness. MCS should not
be reduced to anticipation of litigation and
fiscal liability. 
Mental illness is stigmatized in our soci-
ety and is discriminated against in long-term
disability insurance plans as well as in some
health insurance plans. It would be unfair to
define MCS as a mental illness if the disease
is actually caused by chemical injury. 
Peggy L. Davis
Private citizen 
Atlanta, Georgia
E-mail: Davilou@aol.com
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scientists and grantees are performing basic studies of our susceptibility to environment-
related disease: demonstrating that a carcinogen in cigarette smoke (benzo(a)pyrene) alters part of a
gene to cause lung cancer . . . showing the effects of fetal exposure to PCBs . . . developing a strain of
mouse that lacks functional estrogen receptors and that helps evaluate how some pesticides and other
estrogen-like compounds might affect development and reproduction . . . discovering the genes for
breast, ovarian, and prostate cancers . . . identifying women’s optimal days of fertility . . . seeking to
reverse the damage from lead exposure . . . finding alternatives to traditional animal tests . . . pinpointing
the functions of specific genes by eliminating them from specially bred mouse lines . . . discovering a way,
using ordinary yeast cells, to isolate and clone genes and other fragments of genetic material more
quickly . . . showing the effects of urban air on lung function . . .
A part of the National
Institutes of Health, 
the National Institute
ofEnvironmental Health
Sciences is located in
Research Triangle Park,
North Carolina.
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National Institute of Environmental Health Sciences
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